
The dead will be many from @SenSanders @AOC’s virtue signalling on drug price controls (effects of 22% manufacturing price cut)
16 Feb 2019 Leave a comment
in applied price theory, applied welfare economics, health economics, politics - USA Tags: drug lags, price controls, The fatal conceit
High prices for the newer, safer Insulin Drives Diabetics to Take Extreme Measures
11 Jan 2019 Leave a comment
in economics of regulation, health economics, law and economics, politics - USA, property rights Tags: creative destruction, drug lags, monopoly and competition, patents and copyrights
Why did @medsafe duplicate overseas drug testing? The dead are many from drug lags.
08 Nov 2018 Leave a comment
in economics of regulation, health economics, politics - New Zealand Tags: drug lags

Milton Friedman: The Food and Drug Administration and Self Interest
28 Sep 2018 Leave a comment
in applied price theory, economics of bureaucracy, economics of regulation, health economics, Milton Friedman, politics - USA, Public Choice Tags: drug lags
The Most Dangerous Monopoly: When Caution Kills
13 Mar 2018 Leave a comment
in applied price theory, applied welfare economics, economics of information, economics of regulation, environmental economics, health economics Tags: drug lags, Drug safety, Product safety, The fatal conceit
The Most Dangerous Monopoly: When Caution Kills
25 Feb 2018 Leave a comment
in applied price theory, applied welfare economics, comparative institutional analysis, economic history, economics of information, economics of regulation, health economics, law and economics Tags: drug lags
35% of drug development costs are for safety testing, 65% are for efficacy testing
02 Feb 2017 Leave a comment
in applied price theory, economic history, economics of regulation, health economics Tags: drug lags, Drug safety
Terminally Ill Patients and the Right to Try
29 Jun 2016 Leave a comment
in economics, health economics Tags: drug lags, FDA, invisible graveyard
Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion
03 May 2016 Leave a comment
in economics of media and culture, health economics Tags: drug lags
The $2,558 million figure per approved compound is based on estimated:
- Average out-of-pocket cost of $1,395 million
- Time costs (expected returns that investors forego while a drug is in development) of $1,163 million
Estimated average cost of post-approval R&D—studies to test new indications, new formulations, new dosage strengths and regimens, and to monitor safety and long-term side effects in patients required by the U.S. Food and Drug Administration as a condition of approval—of $312 million boosts the full product lifecycle cost per approved drug to $2,870 million. All figures are expressed in 2013 dollars.
Source: PR Tufts CSDD 2014 Cost Study | Tufts Center for the Study of Drug Development
@mattyglesias on why greedy drug companies are heroes
20 Mar 2016 Leave a comment
in economics of regulation, health economics, law and economics, politics - New Zealand, politics - USA, property rights Tags: avoiding difficult choices, drug lags, generic drugs, intellectual monopolies, invisible graveyard, patents and copyrights





Recent Comments